ArticleScientific reports2026
Expired apheresis platelet-derived exosomes promote cutaneous wound healing.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Exosomes derived from apheresis platelets (AP-Exos) can regulate cellular functions and promote tissue regeneration; however, the characteristics and therapeutic efficacy of exosomes from expired apheresis platelets remain unclear. This study evaluated the properties of exosomes derived from apheresis platelets stored for 7 days (D7-Exos) and their role in skin wound repair. Exosomes were isolated from apheresis platelets stored for 3 days (D3-Exos) and 7 days, and their morphology, particle size, growth factor content, and biological effects on keratinocytes, fibroblasts, and endothelial cells were examined. The potential involvement of the PI3K/Akt signaling pathway in HUVEC was investigated. A full-thickness skin defect model was established in rats to compare the therapeutic efficacy of D3-Exos, D7-Exos, and platelet lysate (PL). D7-Exos showed higher particle concentration and elevated levels of TGF-β1 and PDGF-BB compared with D3-Exos. They significantly promoted cell proliferation, enhanced collagen secretion in HSF, and increased VEGF secretion and angiogenic capacity in HUVEC. D7-Exos activated the PI3K/Akt signaling pathway in HUVEC and upregulated VEGF expression. In vivo, D7-Exos markedly accelerated wound closure, re-epithelialization, and collagen deposition, with better efficacy than D3-Exos and PL. D7-Exos are enriched with multiple growth factors, promote VEGF secretion in HUVEC via activation of the PI3K/Akt pathway, and accelerate wound healing, suggesting potential as a candidate therapeutic approach for skin injury, pending further preclinical validation and safety assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.